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Cirrhosis and chronic liver disease are common illnesses that cause high mortality and 
require treatment. Medication use in these patients may be challenging because of 
idiosyncratic or dose dependent drug toxicity. Therefore, drug choice and drug dose 
adaptations play an important role.  The objective of this clinical review is to discuss the 
literature about and challenges in drug use in patients with chronic liver disease. 
To make good decisions regarding drug choice and dose adjustments in these patients, 
well defined clinical information about diagnoses and laboratory results (creatinine, 
International Normalized Ratio, bilirubin and serologies) as well as in some instances 
pathological findings like liver biopsies are needed. In a second step, these data should be 
organized in electronically supported clinical decision systems, which can then assist 
providers in making choices about medication selection and dosage. 
In summary, while substantial research has been done in the field of drug use in 
patients with liver dysfunction, a great deal also remains to be learned.  Although many of 
these patients can now be identified, it is still very difficult to assess their individual level of 
hepatic function.  The degree of risk associated with drug use and how best to use medications 
in these patients represents an important area for further study.  In the future, 
pharmacogenomics and electronic linking of clinical data may well prove helpful for making 




Cirrhosis and other chronic liver diseases (CLD) are common illnesses in the general 
population, which lead to additional hospitalizations, medical treatment and a high mortality 
in affected patients. According to the National Center for Health Statistics, the age-adjusted 
death rate in 2004 was 9.0/100,000 US inhabitants per year dying of  CLD making it the 
twelfth leading cause of death(1). One recent study found that 1.7% of patients in a population 
in the greater Boston area suffered from CLD (2). 
Serious drug-induced liver failure represents the leading identifiable cause of acute 
liver failure in the United States (3, 4). Drugs may be idiosyncratically hepatotoxic or have 
dose dependent hepatoxicity. In one cohort study with 461 cases of drug-induced liver injury, 
53% of patients had to be hospitalised and  4% suffered severe liver failure; of these, 12 died 
and 6 received a liver transplant(5). In the mentioned study, 32% of the culprit substances 
were antibiotics, 17% neurotropic drugs, 17% musculoskeletal and 10% gastrointestinal 
active drugs. In the United Network for Organ Sharing (UNOS) database (1990-2002), 
acetaminophen alone or in combination accounted for 49% of liver transplantation cases (3).  
Drugs are metabolized and excreted almost exclusively by the liver and the kidneys. 
Failure of one of these organ systems may have an important impact on patient safety and 
drug dose adjustment. In patients with chronic renal insufficiency, it has been well established 
that dosages of nephrotoxic and renally excreted drugs should be adjusted, and some drugs 
should probably be avoided altogether (6, 7).  In these patients, rates of adverse drug events 
have recently been shown to reach 10% of admissions(8). Many drugs are hepatically 
metabolized, and it stands to reason that it might make sense to alter dosages and avoid 
certain medications in patients with CLD, although it has been much less clear how important 
this is relative to the situation in chronic renal insufficiency. 
 5
This review addresses issues of the diagnosis of chronic liver illness, estimating the 
hepatic functional status, mortality risk stratification and drug choice in CLD. We reviewed 
the literature on this topic of the last 10 years adding single older landmark papers as well. 
 
2. Diagnosis of Chronic Liver Illness 
Clinical judgment plays a key role in the diagnosis of the liver disease, but objective 
parameters such as laboratory values, liver biopsy and serologies are also important. Liver 
biopsy remains the gold standard for assessment and staging of liver inflammation and 
fibrosis before potential treatment(9, 10) but is no longer needed to establish the diagnoses of 
chronic hepatitis B or C(11). There are several biopsy scores for the stages of liver 
inflammation and fibrosis with no final consensus on which score to use; three of the most 
used are mentioned in the following.  First, Knodell et al (1981) published a score involving 
both inflammation and fibrosis (12); the Scheuer system (1991) described for the first time 
inflammatory grading and fibrosis staging separately(13).  Five years later the French 
METAVIR group consisting of several hepatology specialists published a score using grading 
of inflammation from A0 (no inflammatory activity) through A3 (severe inflammation) as 
well as fibrosis staging from F0 (no fibrosis through F4 (cirrhosis)(14).  
Serology is used to screen for hepatitis B and C for more than a decade using enzyme 
immunoassay (EIA) also called enzyme-linked immunosorbent assay (ELISA)(15). These 
tests bind to antigenic proteins such as the recombinant C-100 protein from the hepatitis C 
virus(15). Third generation ELISA tests for hepatitis C show a sensitivity of 94-100% and a 
specificity of 97-98.8% compared to the reference of polymerase chain reaction (PCR) in a 
review of evidence for the U.S. Preventive Services Task Force(16). Hepatitis B (HBs) 
antigen is generally acknowledged to be the hallmark of chronic hepatitis B. Today, HBs 
antigen, HBe antigen and HBV DNA levels are analyzed in chronic hepatitis B(17). HBs 
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antigen titres correlate with HBV DNA levels in different stages of chronic hepatitis B except 
in HBe antigen negative hepatitis B(17).  
The most commonly used diagnosis classification systems are the International 
Classification of Diseases (ICD)-9-CM and ICD-10.  ICD-9-CM (clinical modification) is the 
official system of assigning codes to diagnoses and procedures associated with hospital 
utilization in the United States(18). In ICD-9-CM, chronic liver disease and cirrhosis are 
coded in 571 and chronic viral hepatitis is coded in 070.3 (chronic hepatitis B) and 070.54 for 
chronic hepatitis C. In ICD-10, diseases of the liver are coded K70-K77 and chronic viral 
hepatitis B18(19).  
Sociodemographic factors may influence the prevalence of certain disease etiologies in 
CLD. As an example, of 20,158 patients with CLD in one recent study located in the urban 
area of Boston 30.1% of patients were diagnosed with chronic hepatitis C, 7.5% with chronic 
hepatitis B and 1.8% with biliary cirrhosis; the diagnoses associated with alcohol abuse made 
up for 8.4% of patients(2). In contrast, Said et al found in their in-patient university hospital 
setting of 2,859 patients in Wisconsin, that 29.9% of patients suffered from alcohol associated 
liver disease and 21.8% from hepatitis C(20). Therefore, comparing cohorts with chronic liver 
disease warrants diligent comparison of sociodemographic factors and comorbidities. 
 
3. Estimating hepatic functional status and mortality risk stratification 
Liver function assessment may be challenging because of lack of an endogenous 
marker such as creatinine in renal failure(21). Generally, laboratory parameters such as 
aminotransferases, bilirubin, alkaline phosphatase (AP), albumin and prothrombin time 
(International Normalized Ratio, INR) are used. Single laboratory parameters such as 
aminotransferase levels have been suggested to estimate liver functional status and patient 
outcome(22-24). However, the differential diagnoses of elevated liver aminotransferase levels 
are broad and include infections with hepatitis A, B and C, Ebstein-Barr (EBV) and 
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cytomegaly (CMV) viruses, chemotherapy, hepatic steatosis, hepatic fibrosis among many 
others. Furthermore, alanine aminotransferase (ALT) levels may show dependency on body 
mass index (BMI) and gender(25); even caffeine seems to have an impact on ALT levels(26).  
Therefore, causality and predictive power of single tests have been challenged and patterns of 
liver function tests with or without clinical parameters have been developed but are rarely 
diagnostic.  
One of the earliest and most widely applied mortality prediction models, the Child-
Turcotte-Pugh (CTP) classification, relies on clinical judgement (encephalopathy, ascites) and 
laboratory parameters (INR, bilirubin, albumin) with all parameters being measured on a three 
point scale(27-29). It was developed more than thirty years ago to assess preoperative risk 
before esophageal shunt operations in patients with liver dysfunction. However, several 
groups have challenged the CTP score in recent years. Above all, observer dependency with a 
low kappa coefficient regarding clinical patient characteristics and the iatrogenic influence on 
plasma albumin level have been criticized (30). Newer models such as the Model for End-
Stage Liver Disease (MELD) have been successfully developed and use laboratory parameters 
only (3.8 x loge (bilirubin, mg/dL) + 11.2 x loge (INR) + 9.6 x loge (creatinine, mg/dL)+6.4) 
(30, 31).  The MELD score has been used in many clinical settings, such as to predict patient 
outcome in liver transplantation, insertion of transjugular intrahepatic portosystemic shunts, 
alcoholic hepatitis, and to predict fulminant hepatic failure in patients admitted for 
acetaminophen toxicity (28, 30, 32-34). Its generalizability to patients with diverse etiologies 
of liver disease and over longer periods of time is not clear. Its predictive capacity regarding 
mortality in patients with alcohol-induced, postnecrotic or primary-biliary cirrhosis has been 
reported to reach 78% (95% CI 0.74-0.81) over a period of three months (31). The predictive 
power of the MELD score over the CTP score has been challenged; above all the CTP 
adapted with creatinine as one of its score factors seems to predict mortality with a similar c-
statistic (35, 36). Nevertheless, CTP depends on clinical assessments such as encephalopathy 
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and ascites, which might not be readily documented and might vary among physicians of 
varying clinical experience. The advantage of the MELD score is its objectivity and 
independence regarding clinical skills and experience of the examining physician.  
Both the CTP and the MELD scores allow stratification of patients with chronic liver 
disease with respect to risk of mortality(2, 37). Above all the MELD score has been well 
studied in this regard and is used for organ allocation in liver transplantation(30). Wiesner at 
al found a 3-months mortality of 1.9% in patients with CLD and a MELD score of </=9 and a 
3-months mortality of 71.3% in patients with a MELD score of =/>40(30) while Kamath et al 
found respective 3-months mortality rates of 1-8% (MELD score </=9) and 100% (MELD 
score =/>40)(31). Modification of the CTP score has resulted in a similar predictive power 
regarding mortality compared to the MELD score(29). 
 
4. Drug Properties and Choice 
Drug properties like the extrarenally excreted fraction, plasma protein binding and 
metabolism pathways in the liver and kidneys also affect how much viable liver tissue is 
needed to properly metabolize and excrete a specific drug. To this day, there exists no exo- or 
endogenous substance to estimate the hepatic clearance of drugs comparable to creatinine 
clearance in renal failure although many substances have been evaluated(21). Another issue is 
direct liver toxicity of certain drugs. Methods to guide clinicians in drug choice and dose 
adjustments in chronic liver disease are badly needed. There is a wide array of literature on 
dose adjustment with respect to general principles of hepatic drug clearance and single drug 
dose adjustments in patients with cirrhosis (21, 38).  However, many issues regarding liver 
drug metabolism in CLD remain. 
Specifically, some of the main questions are: (1) What are key characteristics of drugs 
regarding liver metabolism?  (2) Which drugs are directly hepatotoxic? What kind of liver 
injury do they inflict? (3) What are the kinetics of specific drugs in patients with liver 
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dysfunction? Secondary questions are: If little is known about the metabolism of a specific 
drug in chronic liver disease, should it be prescribed, and in situations when it is, on what 
grounds should the drug dose for an individual patient be selected?   
4.1 Key characteristics of drugs regarding liver metabolism  
There are many different ways to classify hepatic drug metabolism.  However, the key 
drug class regarding hepatic metabolism in chronic liver illness are drugs with a high hepatic 
flow-limited extraction. High extraction drugs typically show a liver clearance that is > 60% 
flow dependent, and flow is diminished in cirrhosis. This implies that the first pass effect of 
these drugs is reduced in chronic liver disease and free serum levels are expected to be higher 
than normal. ClHep = Q x E where ClHep is the hepatic clearance of a drug, Q = blood flow 
through liver and E = hepatic extraction of drug(21). The following are examples of drugs 
with a high hepatic extraction rate of >60% (= first pass effect) in healthy humans; they 
therefore show a clinically relevant flow dependent hepatic metabolism requiring dose 
reduction in liver illness: cyclosporine, fluorouracil, idarubicin, lovastatin, morphine, 
pentazocine, quetiapine, tacrolimus, verapamil, vinblastine and vincristine(21, 38).  
4.2 Direct hepatotoxicity: Drugs and types of inflicted liver injury  
Directly hepatotoxic drugs represent another issue, and the toxicity they cause can be 
dangerous and costly. Some of them like antiepileptics and tuberculostatics are used quite 
commonly in patients with chronic liver disease. Different patterns of hepatotoxicity have 
been discussed and they may or may not be predictable(39-41); most commonly, the approach 
is either clinically, by means of laboratory values, histo-pathologically or a combination of 
these. The clinical approach may show features such as acute hepatitis (acetaminophen, 
isoniazid, nevirapine, ritonavir, troglitazone), chronic hepatitis (dantrolene, diclofenac, 
methyldopa, minocycline, nitrofurantoin), acute cholestasis (ACE-inhibitors, 
amoxicillin/clavulanic acid, chlorpromazine, erythromycine, sulindac) or a mixed pattern like 
phenytoin or sulfonamides(40, 42). The laboratory approach may show patterns of liver injury 
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including the hepatocellular pattern with an elevated alanine transferase (ALT; e.g. 
acetaminophen, allopurinol, amiodarone, NSAIDs, statins and valproic acid), the cholestatic 
pattern with elevated total bilirubin and alkaline phosphatase (ALP; e.g. amoxicillin-
clavulanic acid, anabolic steroids, clopidogrel and oral contraceptives) as well as the mixed 
pattern with elevated ALP and ALT (e.g. azathioprine, carbamazepine, phenytoin and 
trimethrim-sulfomethoxazole)(39, 43). Histo-pathologically, the most common features are 
the microvascular steatosis with small fat droplets  in the hepatocytes (valproic acid, 
tetracyclines, non-reverse transcriptase inhibitors), acute hepatitis with hepatocellular 
swelling, inflammatory changes with disarray of the portal triad (e.g. isoniazid), cholestatic 
injury with hepatocellular swelling and bile-stained hepatocytes (amoxicillin/clavulanic acid, 
chlorpromazine) and eosinophil-containing inflammation (e.g. phenytoin)(40, 43). Other 
histo-pathological features include non-alcoholic steatohepatitis after exposure to amiodarone 
and tamoxifen, cirrhosis after methothrexate and methyldopa as well as veno-occlusive 
disease after busulfan and cyclophosphamide(40, 41). Granulomatous hepatitis is known to 
occur after carbamazepine, allopurinol and halothane exposure among others(41, 44). In rare 
cases, submassive to massive hepatic necrosis has been observed (indomethacin, labetalol, 
nicotinic acid, valproic acid and trazodone)(41). 
4.3 Pharmacokinetics in patients with liver dysfunction 
Predictive pharmacokinetic models for patients with chronic liver disease are scarce 
because of the highly complex metabolic circumstances in each individual. Not only does the 
kind and degree of liver disease and the drug properties play an eminent role, but chronic liver 
disease and above all cirrhosis also affect other organ systems such as the intestine, the lungs 
and the kidneys. In chronic liver disease, the drug dose usually does not have to be adapted 
unless there is a cirrhosis of the liver(45). 
In cirrhosis, all three pharmacokinetic phases are affected, namely absorption, 
distribution and elimination of the drug. Because of the high portosystemic pressure, drugs 
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won’t be absorbed as readily in the gastrointestinal tract. The reduced presystemic 
metabolisation in the liver leads to a higher bioavailability of intermediate to high extraction 
drugs as outlined above(21, 38). Examples of intermediate to high extraction drugs and their 
increase in bioavailability in cirrhosis are +132% in flumazenil, +115% in morphine, +100% 
in midazolam, +91% in labetalol and +60% in verapamil (38). The distribution process into 
the body compartments depends on the unbound fraction of the drug. The distribution volume 
is getting larger for protein-bound drugs, since albumin and other plasma proteins are 
lowered. The same is true for water soluble drugs, because of the volume overload and ascites 
in patients with cirrhosis(38). Drug elimination is impaired in hepatic cirrhosis by a reduced 
cell mass of functional hepatocytes and their enzymes. Of the two main enzyme systems 
within the hepatocytes, the P450 family with its six known subunits seems to be more affected 
by liver disease than glucuronidation by the uridinediphosphate (UDP)-
glucoronosyltransferase (GT) family(46); it has been suggested that UDP-GT is even up-
regulated in cirrhosis(47). Intra- or extrahepatic biliary obstruction may block drug 
elimination and change pharmacokinetics. Intrahepatic cholestasis may be caused by drugs 
such as erythromycin, amoxicilline/clavulanic acid or ACE-inhibitors, primary sclerosing 
cholangitis, during pregnancy or the familial progressive form(48, 49). Diseases such as bile 
duct stones, cancer of the bile duct and pancreas may cause extrahepatic cholestasis.  
Renal excretion is an important in two ways: 1) most drugs are excreted at least partially by 
the kidneys and 2) chronic liver disease is often accompanied by renal failure. Unfortunately, 
neither serum creatinine levels nor creatinine clearance seem to be fully reliable markers of 
the renal dysfunction commonly associated with liver disease since muscle mass often is 
diminished and the estimated glomerular filtration rate by Cockroft-Gault may therefore be 
too high (45).  
4.4 Pharmacogenetics 
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The science of the influence of the individual genetic pattern on drug metabolism is 
developing fast. For example, it has been recognized that breast cancer is a genetically 
heterogeneous disease and that the presence of the HER2 oncogene has an influence on the 
treatment success with trastuzumab(50). Furthermore, it is well known that genetic patterns of 
the cytochrome P 450 in the liver have an influence on drug metabolism; e.g. the anti-estrogen 
tamoxifen is metabolized by the CYP 2D6 subfamily of the P 450 enzyme complex. A recent 
publication found that tamoxifen is metabolized more or less due to genetic variation in the 
CYP 2D6 enzyme influencing prognosis and recurrence of breast cancer (51). Therefore, 
knowledge of genetic patterns of liver metabolism may have a direct impact on patient life 
expectancy. Although powerful tests are already available commercial solutions are still 
lacking and warrant further research(52, 53). 
4.5 Dose adjustment in single drugs 
To our knowledge, there exists no systematic, clinically feasible way to adjust drug 
dosage in patients with chronic liver illness. As a rule of thumb, it has been suggested that 
there is no need for dose adjustment unless cirrhosis of the liver is present(45). As we may not 
know whether cirrhosis is present in an individual patient, data from observational studies are 
needed. There are certain drug classes that are associated with higher mortality in these 
patients and therefore may warrant dose reduction or even stopping of the drugs. A recent 
study found that the anti-cancer drugs docetaxel (hazard ratio (HR) 7.53, 95% CI 3.91-14.48) 
and oral etoposide (HR 3.55, 95% CI 2.15-5.87), oral morphine (HR 2.26, 95% CI 1.78-2.86) 
as well as the immunosuppressant sirolimus (HR 1.81, 95% CI 1.02-3.21) were associated 
with higher mortality in patients with chronic liver disease. This results remained even after 
adjustment for a cancer diagnosis, liver disease, age and laboratory values (bilirubin, 
creatinine and INR), although it cannot be concluded these associations were causal(2).  
The anti-cancer drug docetaxel causes adherence of microtubuli to each other within 
the cell and therefore inhibits DNA, RNA and protein synthesis. It is used in breast cancer, 
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metastatic prostate cancer, non-small cell lung cancer and gastric adenocarcinoma. The 
Federal Drug and Food Administration (FDA) issued the following drug labelling because of 
its liver toxicity. Docetaxel should not be administered if the total bilirubin is greater than the 
upper limit of normal (ULN) or AST/ALT are higher than 1.5 times ULN and alkaline 
phosphatase (AP) is higher than 2.5 times ULN(54). If AST and/or ALT are elevated up to 1.5 
times ULN with AP and bilirubin within normal limits, 100% of the normal dose should be 
applicable. With AST/ALT between 1.6 to 6.0 times ULN only 75% of the normal dose 
should be used(55). Treating physician should reconsider using docetaxel above this 
threshold. 
The topoisomerase II inhibitor etoposide causes DNA strand breaks and is used against small 
cell cancer, lymphoma and refractory testicular cancer among others. Although generally not 
considered hepatotoxic in standard doses, there have been cases reports on severe 
hepatocellular injury(56). Suggestions are to reduce the dose to 50% if AST levels are >160 
U/L or >3 times ULN and bilirubin levels between 1.5 – 3.0 mg/dL(55, 56). 
In addition, the use of oral morphine was associated with a more than twofold higher 
mortality in patients with chronic liver illness even after adjustment for liver disease and 
cancer(2). This might be due to the high extraction (>60%) in the liver impaired by liver 
illness(21). Another potential reason for the association, though,  is the use of this drug in 
end-of –life situations which may lead to a selection bias in epidemiologic studies(57). We 
suggest that caution is warranted using oral morphine in these patients because of its 
metabolism and patients need to be well monitored for alertness and respiratory rate. 
The macrolide antibiotic and immunosuppressant sirolimus has also been shown to be 
associated with an almost twice as high a mortality in patients with persistent liver disease(2). 
Since the drug is used for solid organ transplantation such as the kidney, the higher mortality 
may reflect an intrinsic toxicity or the influence of the underlying disease. One study found 
significant differences to other immunosuppressants regimes after kidney transplants 
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suggesting intrinsic sirolimus toxicity, such as more biopsy proven transplant rejections and a 
lower glomerular filtration rate(58, 59). Serious adverse events were more common in the 
sirolimus group compared to the other immunosuppressants. Unlike other 
immunosuppressants e.g. cyclosporin, sirolimus does not seem to promote de novo cancer 
growth nor metastasizing by inhibiting angioneogenesis(60). Since sirolimus belongs to the 
group of high extraction drugs (>60%) and shows a potential for causing kidney damage that 
may facilitate hepato-renal syndrome, we suggest avoiding the drug in patients with persistent 
liver disease. If it is needed, we suggest using the minimum drug dose possible, and 
monitoring serum levels as well as checking regularly for side effects. 
 
5. Potential models for drug dose adaptation and future research 
Individual drug dose adaptation in chronic liver illness with potentially hepatotoxic 
drugs remains a challenge. Before marketing, kinetics of a drug are generally estimated from 
healthy individuals; in the post marketing phase there is little incentive for companies to 
evaluate kinetics in patients with disease let alone single diseases. One way to tackle the 
challenge next to kinetics is to combine objective patient and drug informations and to derive 
from there a prognostic stratification as well as the best possible choice of drug and its 
dosage. 
Patient information should include sociodemographic parameters, information about 
the liver disease, comorbidities, laboratory parameters and in the future pharmacogenomic 
information. Data about the drug should include its intrinsic potential of liver toxicity, known 
kinetics in liver disease, usual dosage patterns, time span between applications and total 
amount applied. Smart IT-supported clinical decision support systems could provide the 





 A great deal of additional research is needed in this area.  Clearly, research in how 
pharmacogenomics affects hepatic metabolism is needed.  In addition, we believe it will be 
helpful to integrate clinical data to predict outcome and support dosing recommendations, as 
well as sociodemographic informations, diagnosis, liver function tests, type of drugs applied 
and their expected liver metabolism.  Work is also needed to help make recommendations 
about whether some drugs should be avoided altogether, and whether dosing should be 
altered.  Eventually, electronic decision support systems should guide the clinician through 
the process of prescribing the correct drug in the correct dose in patients with liver disease, as 
has become possible in patients with renal insufficiency(7). 
 
7. Conclusions 
 While substantial research has been done in this area, a great deal also remains to be 
learned.  Many patients with chronic liver dysfunction can now be identified, although it is 
still a challenge to assess the level of  metabolic function in patients with CLD.  The degree of 
risk associated withto the use of medications that show a high hepatic extraction rate or that 
are directly hepatotoxic in this population represents an important area for further study. 
While single drug classes such as anticancer drugs or immunosuppressants show a well 
documented hepatotoxicity, the use of many other medications remains to be defined in 
patients with CLD.   
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